Patent intelligence · AR
AR 123726
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA Y TIENO[3,2-H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA Y TIENO[3,2-H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
Patent details — AR 123726
- Jurisdiction
- AR
- Status
- granted
- Grant date
- Jan 4, 2023
- Expiration
- Dec 30, 2042
- CPC classes
- A61K 31/ 505 A I, A61K 31/ 517 A I, A61P 35/ 00 A I, A61P/3500
Quick answer
AR 123726 (DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA Y TIENO[3,2-H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER) is held by BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]. Status: granted. Granted Jan 4, 2023. Expires Dec 30, 2042 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 505 A I, A61K 31/ 517 A I, A61P 35/ 00 A I, A61P/3500
More from BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]
Related pharmaceutical patents in our USPTO index.
-
AU 2024384453
CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
PT 3886798
COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
US 20260042800
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
WO 2025114603
COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES
granted -
WO 2024094329
PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM
granted -
CA 3268414
MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS
granted -
AU 2022323463
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
AR 127448
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
granted
Frequently asked questions
What is US patent 123726?
AR 123726 (DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA Y TIENO[3,2-H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER) is held by BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]. Status: granted. Granted Jan 4, 2023. Expires Dec 30, 2042 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AR 123726?
BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AR 123726 expire?
Our index shows an expiration date of Dec 30, 2042 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.